Education
About Us
Working with TipRanks
Follow Us
Delta-Fly Pharma, Inc. (JP:4598)
:4598
4598 Stock Chart & Stats
¥507.00
-¥3.00(-0.55%)
At close: 4:00 PM EST
¥507.00
-¥3.00(-0.55%)
Day’s Range― - ―
52-Week Range¥215.00 - ¥793.00
Previous CloseN/A
Volume237.90K
Average Volume (3M)379.72K
Market Cap
¥2.72B
Enterprise Value¥2.26B
Total Cash (Recent Filing)¥730.32M
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.61
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding12,159,900
10 Day Avg. Volume693,770
30 Day Avg. Volume379,723
Financial Highlights & Ratios
PEG Ratio1.82
Price to Book (P/B)18.22
Price to Sales (P/S)0.00
P/FCF Ratio-2.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Delta-Fly Pharma, Inc. News
4598 FAQ
What was Delta-Fly Pharma, Inc.’s price range in the past 12 months?
Delta-Fly Pharma, Inc. lowest stock price was ¥215.00 and its highest was ¥793.00 in the past 12 months.
What is Delta-Fly Pharma, Inc.’s market cap?
Delta-Fly Pharma, Inc.’s market cap is ¥2.72B.
When is Delta-Fly Pharma, Inc.’s upcoming earnings report date?
Delta-Fly Pharma, Inc.’s upcoming earnings report date is May 14, 2026 which is in 89 days.
How were Delta-Fly Pharma, Inc.’s earnings last quarter?
Currently, no data Available
Is Delta-Fly Pharma, Inc. overvalued?
According to Wall Street analysts Delta-Fly Pharma, Inc.’s price is currently Overvalued.
Does Delta-Fly Pharma, Inc. pay dividends?
Delta-Fly Pharma, Inc. does not currently pay dividends.
What is Delta-Fly Pharma, Inc.’s EPS estimate?
Delta-Fly Pharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Delta-Fly Pharma, Inc. have?
Delta-Fly Pharma, Inc. has 12,159,900 shares outstanding.
What happened to Delta-Fly Pharma, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Delta-Fly Pharma, Inc.?
Currently, no hedge funds are holding shares in JP:4598
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Delta-Fly Pharma, Inc.
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase III clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer. Delta-Fly Pharma, Inc. was incorporated in 2010 and is headquartered in Tokushima, Japan.
Technical Analysis
OncoTherapy Science
―
Chiome Bioscience Inc.
―
Oncolys BioPharma, Inc.
―
BrightPath Biotherapeutics Co.Ltd.
―
Kringle Pharma, Inc.
―